FDA Expected To Review Antidepressant Advisory Cmte. Findings At House Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
House Commerce/Oversight Subcommittee convenes Sept. 23 to resume inquiry into antidepressant use in children, methods to handle safety data. FDA may also be questioned on clinical trial registries and off-label promotion.